Fructose-1,6-bisphosphatase-1 inhibitors are primarily used in the field of metabolic research and drug development, particularly for conditions related to glucose metabolism. These inhibitors play a key role in studying gluconeogenesis, a metabolic pathway that generates glucose from non-carbohydrate sources. By inhibiting fructose-1,6-bisphosphatase-1, researchers can better understand and potentially control excessive glucose production, which is beneficial in managing type 2 diabetes. Additionally, these inhibitors are explored for their potential in treating certain cancers, as some cancer cells rely on gluconeogenesis for growth and survival. Their application in therapeutic settings aims to reduce blood sugar levels and disrupt the energy supply to cancer cells, offering a dual approach in metabolic and oncological research.